کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3027099 | 1182939 | 2015 | 5 صفحه PDF | دانلود رایگان |
• We compare concurrent warfarin and ticagrelor with triple antithrombotic therapy.
• Rates of thrombotic and bleeding events were similar in both groups.
• Concomitant ticagrelor and warfarin appears to be an equivalent alternative.
IntroductionTreatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).Materials and methodsWe identified all ACS patients on DT upon discharge from Helsingborg Hospital and Skåne University Hospital in Malmö and Lund, Sweden, during 2013. Patients on DT were compared with historical controls discharged with TT. Major bleeding was defined in accordance with the HAS-BLED derivation study. Patients were retrospectively followed for three months.ResultsIn total, 107 DT patients were identified and compared with 159 controls on TT. Mean HAS-BLED bleeding risk score and duration of treatment were similar between the groups (HAS-BLED 2.2 +/− 0.8 vs 2.2 +/− 1.0 units, p = NS; duration 2.7 +/− 0.8 vs 2.5 +/− 0.9 months, p = NS; DT vs TT). The incidence of spontaneous major bleeding was similar between the groups, as was a composite of all thrombotic events, i.e. peripheral embolism, stroke/TIA and acute coronary syndrome (bleeding 8/106 (7.5%) vs 11/157 (7.0%), p = NS; thrombosis 5/106 (4.7%) vs 5/157 (3.2%), p = NS; DT vs TT).ConclusionsRates of thrombotic and bleeding events were similar in patients with TT and patients with ticagrelor and warfarin.
Journal: Thrombosis Research - Volume 135, Issue 1, January 2015, Pages 26–30